• What is continuous glucose monitoring and how can it help you?

Glucose monitoring data graph

With the Enlite™ glucose sensor and MiniLink™ transmitter, CGM allows you to read your glucose levels at any time- keeping you informed around the clock and giving you the jump on information you need to take action sooner. The transmitter wirelessly transmits readings to your MiniMed Veo insulin pump every 5 minutes. The glucose sensor can be worn for up to 6 days.

Technology based on evidence

MiniMed Veo insulin pump on an adult's bodyContinuous glucose monitoring has been proven to:

  • Reduce A1C levels compared to multiple daily injections or insulin pump technology alone1,2,4,5
  • Detect nighttime hypoglycemia and respond accordingly 6
  • Significantly reduce hypoglycemia events with Low Glucose Suspend 3
  • Helps reduce lows and rebound highs with Low Glucose Suspend 3
  • Proven to reduce hypoglycemia 3,7

The MiniMed Veo is engineered with a Low Glucose Suspend (LGS) feature, that has been clinically proven to reduce hypoglycemia events and has been shown to reduce severe hypo events to 0.3,7 The LGS feature automatically suspends insulin delivery for up to two hours when your glucose levels fall to a preset level.

Built-in CGM functions that can help you manage your diabetes

REAL-Time Glucose Values- see your glucose values every five minutes- It's like having the information of 288 fingerstick readings a day  

REAL-Time Trend Graphs- your glucose level is displayed on your pump screen in 3, 6, 12 and 24-hour periods   

REAL-Time Trend Arrows- single and double arrows point up and down to indicate the degree and direction of your glucose trends 

REAL-Time Predictive Alerts- let's you know when your glucose levels are rapidly changing, trending out of range or are out of range

The 2013 Canadian Diabetes Association Clinical Practice Guidelines recommend that for people living with type 1 diabetes, continuous glucose monitoring may be used to improve glycemic control and reduce hypoglycemia 8.

A CGM Starter Kit is included with every new MiniMed® Veo™ insulin pump

With the increase in clinical evidence supporting the benefit of insulin pump technology integrated with CGM and the recent Canadian Diabetes Clinical Practice Guidelines, every new MiniMed® Veo™ Insulin Pump will include:
  • A MiniLink™ Transmitter
  • An Enlite™ Serter
  • 1 box of 5 Enlite™ glucose sensors

How does CGM work?

You will need to wear a small glucose sensor that sits under the skin for up to 6 days at a time. Just like an infusion set cannula, the sensor is easily inserted using an automatic device provided with the system. The sensor attaches to a small lightweight transmitter that sends glucose sensor data wirelessly to your insulin pump through radio frequency (RF) wireless technology.

The insulin pump displays the glucose data On Screen and plots a Trend Line of the data so that you can see exactly what your glucose trends are and what may be affecting them.

As well as seeing the on-screen display, you can set Alerts on the insulin pump that will sound or vibrate to warn you when you are likely to reach, are reaching or have reached your glucose target limits. 


  • 1 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
  • 2 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320.
  • 3 Bergenstal RM, Klono_ DC, Garg SK. E t al. N Engl J Med. June 22, 2013DOI: 10.1056 / NEJMoa1303576
  • 4 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Effects of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009;32:1378-1383.
  • 5 Slover RH, Welsh JB, Creigo A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2011 Jul 3 [Epub ahead of print].
  • 6 Ahmet A, Dagenais S, Barrowman NJ, et al. Prevalence of Nocturnal Hypoglycemia in Pediatric Type 1 Diabetes: A Pilot Study Using Continuous Glucose Monitoring. J Pediatr. 2011;159:297-302.
  • 7 Ly T.T, Nicholas J.A., Retterath A. et al. Reduction of Severe Hypoglycemia with Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension in Patients with Type 1 Diabetes [abstract]. Diabetes 2013; 62 (supplement 1): 228-OR
  • 8 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2013;37(suppl 1):S1-S212